A Monocentric, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Localized Mucosal Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Toripalimab (Primary)
Indications Anal cancer; Head and neck cancer; Malignant melanoma; Mouth neoplasm; Oesophageal cancer; Rectal cancer; Urethral cancer
Focus Therapeutic Use

11 Nov 2023 Results assessing pathologic response in patients with resectable mucosal melanoma published in the Annals of Oncology.
13 Sep 2022 Status changed from recruiting to active, no longer recruiting.
13 Sep 2022 Results assessing updated data of pathologic response rate, recurrence-free survival at 1.5-years and the multiplex immunohistochemistry analysis before and after surgery, presented at the 47th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com